Sanofi, swot analysis, Strengths, Weaknesses, Opportunities, Threats, supply chain, Doliprane, medication recyclability, plastic waste, metallic waste, biodegradable material, packaging solutions, distribution method, retailers, consumers, product fragility, production methods
By modifying its supply chain and Doliprane production methods, the company could position itself as a leader in sustainable development in the pharmaceutical sector. In particular, it is adopting a new type of packaging based on sodium alginate. This material, derived from algae, decomposes naturally without leaving harmful residues, enabling the company to considerably reduce its carbon footprint through the reduction of plastic packaging.
(...)
The adoption of new materials, even though they are already in use within the Sanofi group, could disrupt the production chain. What's more, it's not hard to imagine that the production chain will have to be partially rethought to incorporate the use of these new biodegradable solutions. Both of these aspects involve costs, and the high nature of the change they impose could upset the balance between sustainability and profitability within the company.
[...] Evolving regulations: Despite the changes envisaged, new regulations and directives, particularly European ones, may be on the horizon, which could upset the company's transition program. Of course, the company is already taking a certain approach, with a completely rethought production chain, from product methods to consumer access. But new standards concerning medical requirements, water treatment or even transport methods could be too disruptive. Without calling the project into question, they could reduce its profitability, and given that the initial investment will be significant, this could be a terrible brake for the company, which would no longer see any financial advantage in it. [...]
[...] While buying through a reusable box may initially be a disruptive experience, the consumer is automatically involved in the company's new circular economy and distribution system, which in turn fosters his or her understanding of environmental and consequently climatic issues. Threats Consumer resistance: Changing the consumption habits of an entire population already accustomed to the common model of cardboard and plastic packaging will not be without its pitfalls. It goes without saying that at least some consumers may refuse to play along and block the change. In which case, the company's very ability to make a profit would be jeopardized. [...]
[...] What's more, the same problem is likely to arise with regard to the distribution system. Transport standards are not in question, and neither is product viability; but it is the intention to change certain carriers that could disrupt flows. What's more, if pharmacies are to distribute both doliprane and the new box, they will need to be fully stocked, or run the risk of no longer being able to sell drug solutions. In this respect, if the implementation plan is not perfectly synchronized with good inventory and transport management, it could spell economic disaster. [...]
[...] SWOT Analysis - SANOFI's change initiative Strengths: - No plastic and metallic wastes This updated packaging solution removes any form of plastic, cardboard, paper or metallic material. These were present in the former solution but did not have a purpose once the medication was taken by the consumer. Thus, it was thrown away after consumption. Using sea plant as a hermetical packaging solution for each unit of Doliprane, which is a biodegradable material similar to a plastic film in the texture and properties, our change initiative is polluting-free. [...]
[...] In particular, it is adopting a new type of packaging based on sodium alginate. This material, derived from algae, decomposes naturally without leaving harmful residues, enabling the company to considerably reduce its carbon footprint through the reduction of plastic packaging. In the same spirit, wholesaling to its distributors - pharmacies - will enable the company to drastically reduce the amount of cardboard and individual plastic packaging used for its doliprane boxes; at the same time, reducing the amount of waste at the end of the consumer chain, facilitating the achievement of recycling targets, and promoting the use of reusable packaging through the widespread distribution of individual boxes that will enable consumers to perceive their medicines while protecting them from the outside environment. [...]
APA Style reference
For your bibliographyOnline reading
with our online readerContent validated
by our reading committee
